Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC3R | P41968 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972564 | 0.85 | CTSK (0.47) | — | |
| SCHEMBL10340351 | 0.82 | MC4R (0.42) | MMP2MC4RLTA4HMC5RMC3R | |
| SCHEMBL10792449 | 0.80 | LTA4H (0.39) | MMP2LTA4HANPEP | |
| SCHEMBL18497919 | 0.77 | SLC7A5 (0.45) | MC4RLTA4HMC5RMC3RSLC7A5 | |
| SCHEMBL10425083 | 0.75 | CTSK (0.44) | SLC7A5 | |
| SCHEMBL30727542 | 0.75 | EPOR (0.38) | LTA4H | |
| SCHEMBL11047397 | 0.75 | SLC7A5 (0.48) | LTA4HSLC7A5 | |
| SCHEMBL11388403 | 0.74 | THRB (0.35) | MMP2SLC7A5THRB | |
| SCHEMBL27519271 | 0.74 | GRM8 (0.30) | THRB | |
| SCHEMBL27519273 | 0.74 | GRM8 (0.30) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723305-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7718619-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713936-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7700561-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7687467-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687466-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7678770-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090131333-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131332-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131335-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124696-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124700-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1865980-A2 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | New River Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006121552-A9 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | NEW RIVER PHARMACEUTICALS INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2006121552-A2 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131332-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20090124700-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20090124696-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20090131333-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20090131335-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | MMP2 2424/4885MC4R 269/4885LTA4H 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.